Oral antiviral agents offer a new treatment option for nonhospitalized adult patients with COVID-19. Hear expert faculty discuss the safety and efficacy data of molnupiravir and nirmatrelvir (PF-07321332) plus ritonavir in outpatient adults with mild to moderate COVID-19.
In this episode, Renslow Sherer, MD, discusses key data on COVID-19 oral antiviral agents—molnupiravir and nirmatrelvir (PF-07321332) plus ritonavir—for nonhospitalized adults with mild to moderate COVID-19, including:
Presenter:
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Review the downloadable slideset at:
https://bit.ly/31wi1Qi
Link to full program:
https://bit.ly/3EH2485